These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29048126)

  • 1. Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.
    Gresch G; Schenke L; Mladenov R; Zwirner S; Cremer C; Niesen J; Grieger E; Brümmendorf T; Jost E; Fischer R; Stockmeyer B; Barth S; Nachreiner T; Stein C
    Br J Haematol; 2018 Oct; 183(2):313-317. PubMed ID: 29048126
    [No Abstract]   [Full Text] [Related]  

  • 2. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
    Mladenov R; Hristodorov D; Cremer C; Hein L; Kreutzer F; Stroisch T; Niesen J; Brehm H; Blume T; Brümmendorf TH; Jost E; Thepen T; Fischer R; Stockmeyer B; Barth S; Stein C
    Int J Cancer; 2015 Dec; 137(11):2729-38. PubMed ID: 26041304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy with immunotoxins.
    Vallera DA
    Methods Mol Biol; 2001; 166():235-46. PubMed ID: 11217370
    [No Abstract]   [Full Text] [Related]  

  • 6. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
    Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S
    Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein.
    Tacken PJ; Hartshorn KL; White MR; van Kooten C; van de Winkel JG; Reid KB; Batenburg JJ
    J Immunol; 2004 Apr; 172(8):4934-40. PubMed ID: 15067073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
    Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
    Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
    Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
    Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
    Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
    Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
    Chiron MF
    Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
    Frankel AE; Sievers EL; Scheinberg DA
    Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
    Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
    Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
    Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH
    Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
    Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
    Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
    Miller JL
    Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.